Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico

There is still a need for safe, efficient, and low-cost coronavirus disease 2019 (COVID-19) vaccines that can stop transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we evaluated a vaccine candidate based on a live recombinant Newcastle disease virus (NDV) that expres...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponce-de-León, Samuel, Torres, Martha, Soto-Ramírez, Luis Enrique, Calva, Juan José, Santillán-Doherty, Patricio, Carranza-Salazar, Dora Eugenia, Carreño, Juan Manuel, Carranza, Claudia, Juárez, Esmeralda, Carreto-Binaghi, Laura E., Ramírez-Martínez, Luis, Paz De la Rosa, Georgina, Vigueras-Moreno, Rosalía, Ortiz-Stern, Alejandro, López-Vidal, Yolanda, Macías, Alejandro E., Torres-Flores, Jesús, Rojas-Martínez, Oscar, Suárez-Martínez, Alejandro, Peralta-Sánchez, Gustavo, Kawabata, Hisaaki, González-Domínguez, Irene, Martínez-Guevara, José Luis, Sun, Weina, Sarfati-Mizrahi, David, Soto-Priante, Ernesto, Chagoya-Cortés, Héctor Elías, López-Macías, Constantino, Castro-Peralta, Felipa, Palese, Peter, García-Sastre, Adolfo, Krammer, Florian, Lozano-Dubernard, Bernardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170424/
https://www.ncbi.nlm.nih.gov/pubmed/37164959
http://dx.doi.org/10.1038/s41541-023-00662-6

Ejemplares similares

Ejemplares similares